Ascenda BioSciences LLC, an Alpharetta, Georgia based clinical testing and diagnostics company, acquired Provista Diagnostics, Inc., an Alpharetta, GA-based women’s early-stage cancer diagnostic company.
The amount of the deal, completed with the financial sponsorship by private equity firm The Strategic Group, P.R., LLC, was not dislcosed.
Provista Diagnostics creates, produces, and markets innovative solutions directed at unmet clinical needs.
Its lead diagnostic, Videssa Breast, is a blood test for the accurate and early detection of breast cancer. With a blood draw, the test can inform whether further diagnostic procedures may be warranted or provide further assurance for those patients that likely do not have breast cancer.
In addition to a breast cancer test, the company has developed a pipeline of blood-based diagnostic tests to address the greatest unmet needs and clinical challenges in women’s cancers, including ovarian, endometrial, and HPV-associated cancers.
Uriel Kusiatin, MBA and Rao V. Mulpuri PhD, MBA, both from Provista Diagnostics, are joining Ascenda BioSciences, as CEO and COO respectfully. Provista Diagnostics is now a major subsidiary of Ascenda BioSciences.
Ascenda BioSciences offers molecular-based technologies to detect multiple bacteria, parasites, viruses, and health risk markers to differentiate between infection and inflammation, address antibiotic resistance and diagnose autoimmune and metabolic disorders with high sensitivity and specificity.